



March 08, 2024

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Intimation regarding execution of Transfer of Partnership Interest Agreement (“TPIA”) for the acquisition of minority interest in HCG EKO Oncology LLP (“HCG EKO LLP”)

Stock Code : BSE – 539787, NSE – HCG

Reference : Regulation 30(3) and (4) read with Schedule III Part A Para A sub-para (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 (“SEBI Circulars”).

We would like to inform you that the Company, EKO Diagnostic Private Limited (“EKO”) and HCG EKO Oncology LLP (“HCG EKO LLP”), subsidiary of the Company, have entered into a Transfer of Partnership Interest Agreement on March 08, 2024 (“TPIA”), for the acquisition of entire partnership interest aggregating to 49.5% of EKO in HCG EKO LLP, by the Company.

With this acquisition, HCG EKO LLP has become wholly owned by the Company, and the Company shall own the entire economic interest of the business operations in Kolkata, which would result in a better financial and operating structure.

Additional disclosures as required under SEBI Circulars to be provided with respect to execution of Transfer of Partnership Interest Agreement:

(a) Name of the target entity, details in brief such as size, turnover etc;

The target entity is HCG EKO Oncology LLP (“HCG EKO LLP”). HCG EKO LLP operates a comprehensive cancer centre in Kolkata, which has a licensed capacity of 88 beds, of which 72 beds are operational as on date. The turnover (revenue from operations) of HCG EKO LLP for the financial year ended March 31, 2023, was INR 40.3 Crores (approx.)

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



- (b) *Whether the acquisition would fall within related party transactions(s) and whether the promoter/promoter group/promoter group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;*

The acquisition of the partnership interest of EKO in HCG EKO LLP would not fall within the related party transaction. None of the promoter/ promoter group/ promoter group companies have any interest in this acquisition.

- (c) *Industry to which the entity being acquired belongs.*

HCG EKO LLP is a provider of specialty health care, focusing on cancer care.

- (d) *Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);*

With this acquisition, HCG EKO LLP has become wholly owned by the Company, and the Company shall own the entire economic interest of the business operations in Kolkata, which would result in a better financial and operating structure.

- (e) *Brief details of any governmental or regulatory approvals required for the acquisition.*

This transaction is not subject to any approvals from any governmental or regulatory approvals.

- (f) *Indicative time period for completion of the acquisition.*

The Company has completed the transaction on March 08, 2024.

- (g) *Nature of consideration – whether cash consideration or share swap and details of the same.*

The consideration for the acquisition of the entire partnership interest of EKO in HCG EKO LLP is in the form of cash.

- (h) *Cost of acquisition or the price at which the shares are acquired.*

The consideration paid to EKO for the transfer of its partnership interest in HCG EKO LLP is INR 20 Crores.

- (i) *Percentage of shareholding/control acquired and/or number of shares acquired.*



The Company, on the completion of acquisition of partnership interest from EKO holds 100% of the capital of HCG EKO LLP.

(j) *Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last years' turnover, country in which the acquired entity has presence and any other significant information (in brief);*

HCG EKO LLP was incorporated on May 15, 2015, as a subsidiary of the Company. The turnover (revenue from operations) of HCG EKO LLP for the financial year ended March 31, 2023, was INR 40.3 Crores (approx.).

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary & Compliance Officer